Skip to main content
Year archive

Spexis AG — 2020 filings

All 20 regulatory filings released by Spexis AG (SPEX) in 2020, sourced directly from the official regulator.

20 Filings
2020 Period
2020 filings (20)
Filing Released Lang
Polyphor receives approval to start first-in-human clinical trial of inhaled antibiotic murepavadin
Regulatory Filings
2020-12-22 English
Polyphor announces third positive Data Safety Monitoring Board (DSMB) recommendation to continue Phase III balixafortide FORTRESS study without modifications
Legal Proceedings Report
2020-12-14 English
Polyphor receives an additional USD 2.3 million award from CARB-X to support ongoing development of a new class of antibiotics targeting multi-drug resistant Gram-negative pathogens
Environmental & Social Information
2020-12-11 English
Polyphor receives award of up to USD 3.3 million from Cystic Fibrosis Foundation to support clinical development of inhaled antibiotic murepavadin
Legal Proceedings Report
2020-11-24 English
Polyphor to Host an Expert Perspectives Webinar on Innovative IO Approaches for the Treatment of HER2 Negative Metastatic Breast Cancer
Report Publication Announcement
2020-11-13 English
Polyphor completes recruitment in Phase III trial of balixafortide in metastatic breast cancer
Regulatory Filings
2020-10-29 English
Polyphor receives CARB-X award of up to USD 18.44 million to support development of new antibiotic program
Regulatory Filings
2020-10-14 English
Polyphor announces closing of Fosun Pharma licensing agreement for balixafortide in China and receipt of $15 million upfront payment
Regulatory Filings
2020-09-29 English
Polyphor to present at the H.C. Wainwright Global Investment Conference
Regulatory Filings
2020-09-11 English
Polyphor announces financial results for the first half 2020
Earnings Release H1 2020
2020-09-03 English
Polyphor and Fosun Pharma announce exclusive licensing agreement for balixafortide in China
Regulatory Filings
2020-08-31 English
Polyphor announces second positive Data Safety Monitoring Board recommendation to continue Phase III FORTRESS study without modifications
Regulatory Filings
2020-08-03 English
Polyphor strengthens financial flexibility with CHF 19.3 million equity-linked financing
Capital/Financing Update
2020-07-28 English
Polyphor shareholders approve all proposals at the Annual General Meeting 2020
AGM Information
2020-06-04 English
Polyphor announces acceptance of balixafortide abstract at the American Society of Clinical Oncology (ASCO) 2020 virtual scientific program
Legal Proceedings Report
2020-05-14 English
Polyphor publishes invitation to the Annual General Meeting 2020
AGM Information
2020-05-05 English
Polyphor announces financial results for the full-year 2019
Earnings Release FY 2019
2020-04-28 English
Polyphor announces positive Data Safety Monitoring Board (DSMB) recommendation to continue Phase III FORTRESS study without modifications
Regulatory Filings
2020-03-30 English
Polyphor announces progress of the Phase III immuno-oncology program with balixafortide. Renewed strategy in advancing antibiotics and oncology research and pipeline
Regulatory Filings
2020-02-20 English
Polyphor appoints Gokhan Batur as Chief Executive Officer
Board/Management Information
2020-01-23 English